Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

NCT00504426 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00504426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
May 31, 2009
Enrollment
101 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pain due to osteoporosis